- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT01889719
A Phase I Study to Evaluate the Safety and Immunogenicity of Heterologous Boost Immunizations With MVA-CMDR
12 februari 2016 uppdaterad av: Rockefeller University
Phase I Study to Evaluate the Safety/Immunogenicity of Boost Immunizations With MVA-CMDR in Healthy Volunteers Previously Immunized With Anti-DEC-205 Monoclonal Antibody Targeted HIV Gag p24 Vaccine Plus Poly-ICLC (RV 365 / WRAIR #2006)
This trial will investigate whether immunizations with an MVA recombinant HIV vaccine are safe and whether they will boost immune responses generated by immunizations with a dendritic cell (DC) targeted protein vaccine, DCVax-001, plus poly ICLC in healthy HIV-uninfected volunteers.
Studieöversikt
Detaljerad beskrivning
This trial will investigate whether immunizations with an MVA recombinant HIV vaccine are safe and whether they will boost immune responses generated by immunizations with a dendritic cell (DC) targeted protein vaccine, DCVax-001, plus poly ICLC in healthy HIV-uninfected volunteers.
Investigators propose to assess the quality of immunity elicited by immunizations with MVA-CMDR only or by booster immunizations with MVA-CMDR in volunteers previously immunized with a DC-targeted HIV vaccine.
This vaccination regimen can provide the proof-of-concept that DC targeted protein vaccines can prime strong immune responses and therefore be valuable in combination with other vaccine modalities against HIV or other diseases.
Studietyp
Interventionell
Inskrivning (Faktisk)
14
Fas
- Fas 1
Kontakter och platser
Det här avsnittet innehåller kontaktuppgifter för dem som genomför studien och information om var denna studie genomförs.
Studieorter
-
-
New York
-
New York, New York, Förenta staterna, 10065
- The Rockefeller University
-
-
Deltagandekriterier
Forskare letar efter personer som passar en viss beskrivning, så kallade behörighetskriterier. Några exempel på dessa kriterier är en persons allmänna hälsotillstånd eller tidigare behandlingar.
Urvalskriterier
Åldrar som är berättigade till studier
18 år till 62 år (Vuxen)
Tar emot friska volontärer
Ja
Kön som är behöriga för studier
Allt
Beskrivning
Inclusion Criteria:
- Have completed protocol SSC-710 and received either DCVax-001 plus poly ICLC, poly ICLC only or sterile saline. If less than 6 volunteers who originally received placebo (poly ICLC only or sterile saline) under protocol SSC_710 are willing to participate and are found eligible to participate in this proposed study, new volunteers can be enrolled as long as they are eligible according to the remaining inclusion and exclusion criteria below.
- Healthy adult males and females, as assessed by a medical history, physical exam, ECG, and laboratory tests;
- Age of at least 18 years of age on the day of screening and no greater than 62 years at time of vaccination;
- Willing to comply with the requirements of the protocol and available for follow-up for the planned duration of the study (screening plus 12 months);
- In the opinion of the principal investigator or designee, has understood the information provided. (Written informed consent needs to be given before any study-related procedures are performed);
- Amenable to HIV risk reduction counseling, committed to maintaining behavior consistent with low risk of HIV exposure through the last required protocol clinic visit;
- Assessed by the clinic staff as being at "low risk" for HIV infection on the basis of sexual behaviors within the 12 months prior to enrollment defined as follows:
- Sexually abstinent OR
- Had two or fewer mutually monogamous relationships with partners believed to be HIV-uninfected and who did not use illicit drugs (illicit drug use or abuse that includes any injection drugs, methamphetamines (crystal meth), heroin, cocaine, including crack cocaine or chronic marijuana abuse) OR
- Had two or fewer partners believed to be HIV-uninfected and who did not use illicit drugs (as defined above) and with whom he/she regularly used condoms for vaginal and anal intercourse;
- If sexually active female, willing to use one effective method of contraception (combined oral contraceptive pill; injectable contraceptive; diaphragm; Intra Uterine Device (IUD); condoms; anatomical sterility in self or partner) at least until 3 months after last immunization. All female volunteers must be willing to undergo urine pregnancy tests at time points as indicated in the Schedule of Procedures.
Exclusion Criteria:
- Confirmed HIV-1 or HIV-2 infection
- Any clinically significant abnormality on history or examination including history of immunodeficiency or autoimmune disease; use of systemic corticosteroids immunosuppressive anticancer, or other medications considered significant by the trial physician within the last 6 months
- Any clinically significant acute or chronic medical condition requiring care of a physician (e.g., diabetes, coronary artery disease, myopericarditis, grand-mal epilepsy, rheumatologic illness, malignancy, substance abuse) that in the opinion of the investigator would preclude participation
- History of clinically significant eczema or chronic urticaria
- Any laboratory value outside of reference range, with the exception of any non-clinically significant Grade I elevations of liver function tests (AST, ALT, direct/total bilirubin), electrolytes (Na, K, Cl, CO2), CBC, urinalysis as determined by the Principal Investigator or his designee
- Baseline ECG with features that would interfere with interpretation of myo/pericarditis including significant repolarization abnormality, bundle branch block, and AV block
- Within the 12 months prior to enrollment, the volunteer has had excessive daily alcohol use or frequent binge drinking or chronic marijuana abuse or any other use of illicit drugs
- Within the 12 months prior to enrollment, the volunteer has a history of newly-acquired syphilis, gonorrhea, non-gonococcal urethritis, herpes simplex virus type 2 (HSV2), pelvic inflammatory disease (PID), mucopurulent cervicitis, epididymitis, proctitis, lymphogranuloma venereum, chancroid, hepatitis B (surface antigen, HbsAg) or hepatitis C (HCV antibodies);
- If female, pregnant, planning a pregnancy during the 3-month follow up period after last immunization, or lactating
- Receipt of a live attenuated vaccine within 30 days or other vaccine within 14 days prior to study vaccination
- Prior use of medications for HIV PrEP
- Receipt of an investigational product (not vaccine-related) within the last 12 months. Receipt of a non-HIV experimental vaccine(s) within the last 5 years in a prior vaccine trial. Exceptions may be made for vaccines that have subsequently undergone licensure by the FDA. For subjects who have received control/placebo in an experimental vaccine trial, or who have received an experimental vaccine(s) greater than 5 years ago, eligibility for enrollment will be determined by the investigators on a case-by-case basis.
- History of severe local or systemic reaction to vaccination defined as:
- Local: extensive, indurated redness and swelling involving most of the major circumference of the arm, not resolving within 72 hours;
- Systemic: fever > 39.5°C within 48 hours, anaphylaxis, bronchospasm, laryngeal edema, circulatory collapse, convulsions or encephalopathy within 72 hours
- History of immediate type hypersensitivity reaction to eggs or egg products
- Major psychiatric illness
- In the opinion of the investigator, unlikely to comply with protocol
Studieplan
Det här avsnittet ger detaljer om studieplanen, inklusive hur studien är utformad och vad studien mäter.
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Grundläggande vetenskap
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Parallellt uppdrag
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
---|---|
Experimentell: Vaccination with MVA-CMDR Group 1
Six to 27 subjects who previously received vaccination with DEC-205, will receive vaccination with MVA-CMDR
|
injections of MVA-CMDR vaccine
|
Aktiv komparator: Vaccination with MVA-CMDR Group 2
Six to 27 subjects who previously did not receive vaccination with DEC-205, will receive vaccination with MVA-CMDR
|
injections of MVA-CMDR vaccine
|
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
---|---|---|
safety and tolerability of MVA-CMDR vaccine
Tidsram: 16 weeks
|
safety and tolerability of two intramuscular injections of MVA-CMDR vaccine candidate in healthy HIV-uninfected volunteers
|
16 weeks
|
Samarbetspartners och utredare
Det är här du hittar personer och organisationer som är involverade i denna studie.
Sponsor
Utredare
- Huvudutredare: Sarah Schlesinger, MD, Rockefeller Univesrity
Studieavstämningsdatum
Dessa datum spårar framstegen för inlämningar av studieposter och sammanfattande resultat till ClinicalTrials.gov. Studieposter och rapporterade resultat granskas av National Library of Medicine (NLM) för att säkerställa att de uppfyller specifika kvalitetskontrollstandarder innan de publiceras på den offentliga webbplatsen.
Studera stora datum
Studiestart
1 januari 2014
Primärt slutförande (Faktisk)
1 maj 2015
Avslutad studie (Faktisk)
1 maj 2015
Studieregistreringsdatum
Först inskickad
20 juni 2013
Först inskickad som uppfyllde QC-kriterierna
26 juni 2013
Första postat (Uppskatta)
28 juni 2013
Uppdateringar av studier
Senaste uppdatering publicerad (Uppskatta)
17 februari 2016
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
12 februari 2016
Senast verifierad
1 februari 2016
Mer information
Termer relaterade till denna studie
Nyckelord
Andra studie-ID-nummer
- SSC-0803
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .
Kliniska prövningar på HIV
-
University of Alabama at BirminghamMobile County Health Deparment; Alabama Department of Public HealthRekryteringHIV | HIV-testning | HIV-koppling till vård | HIV-behandlingFörenta staterna
-
ANRS, Emerging Infectious DiseasesHopital Universitaire Robert-Debre; Institut de Recherche pour le Developpement och andra samarbetspartnersOkändHIV | HIV-oinfekterade barn | Barn som utsätts för HIVKamerun
-
French National Agency for Research on AIDS and...Elizabeth Glaser Pediatric AIDS FoundationAvslutadPartners HIV-testning | Hiv-rådgivning för par | Par kommunikation | Hiv-incidensKamerun, Dominikanska republiken, Georgien, Indien
-
University of MinnesotaIndragenHIV-infektioner | HIV/AIDS | Hiv | AIDS | Aids/Hiv problem | AIDS och infektionerFörenta staterna
-
Hospital Clinic of BarcelonaAvslutadIntegrashämmare, HIV; HIV PROTEAS HÄMMARSpanien
-
University of Maryland, BaltimoreIndragenHiv | Njurtransplantation | HIV-reservoar | CCR5Förenta staterna
-
Erasmus Medical CenterHar inte rekryterat ännuHIV-infektioner | Hiv | HIV-1-infektion | HIV I-infektionNederländerna
-
Africa Health Research InstituteLondon School of Hygiene and Tropical Medicine; University College, London och andra samarbetspartnersRekryteringHIV | HIV-testning | Koppling till vårdSydafrika
-
National Taiwan UniversityRekrytering
-
Helios SaludViiV HealthcareOkändHiv | HIV-1-infektionArgentina
Kliniska prövningar på MVA-CMDR
-
Henry M. Jackson Foundation for the Advancement...Johns Hopkins University; Karolinska Institutet; University of Miami; Chulalongkorn... och andra samarbetspartnersAktiv, inte rekryterande
-
National Institute of Allergy and Infectious Diseases...HIV Vaccine Trials Network; IPPOX Foundation; CHAVI; MHRPAvslutadHIV-infektionerFörenta staterna, Schweiz
-
Instituto Nacional de Saúde, MozambiqueEuropean and Developing Countries Clinical Trials Partnership (EDCTP); Swedish...AvslutadHIV-infektionerMoçambique
-
University of OxfordAvslutad
-
Bavarian NordicAvslutadSyncytialvirusinfektioner i luftvägarnaFörenta staterna
-
TransgeneAvslutadHepatit C, kroniskFrankrike
-
National Institute of Allergy and Infectious Diseases...RekryteringLevertransplantationFörenta staterna
-
Bavarian NordicJPM CBRN MedicalAvslutadHästencefalitFörenta staterna
-
Universitätsklinikum Hamburg-EppendorfErasmus Medical Center; German Center for Infection Research; Coalition for... och andra samarbetspartnersAktiv, inte rekryterandeMERS (Mellanösterns respiratoriska syndrom)Tyskland, Nederländerna
-
Cancer Research UKBarinthus BiotherapeuticsUpphängdEsofagusneoplasmer | Icke-småcellig lungcancer (NSCLC)Storbritannien